Surmodics (SRDX)
(Delayed Data from NSDQ)
$39.53 USD
-0.04 (-0.10%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $39.52 -0.01 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.53 USD
-0.04 (-0.10%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $39.52 -0.01 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Zacks News
Here's Why You Should Retain Glaukos in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.
ABIOMED Unveils Digital Platform CAMP PCI for CAD Treatment
by Zacks Equity Research
ABIOMED's (ABMD) new digital platform helps to deliver better patient outcomes for those suffering from CAD.
Here's Why You Should Add HMS Holdings to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on HMS Holdings (HMSY) stock, thanks to solid prospects.
Can SurModics (SRDX) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Surmodics Gets CE Mark for SurVeil Drug-Coated Balloon
by Zacks Equity Research
Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
Investor confidence is high in LHC Group (LHCG), thanks to solid prospects
Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout
by Zacks Equity Research
Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.
Medtronic Alters ECMO Therapy on New FDA Rules for Coronavirus
by Zacks Equity Research
Medtronic (MDT), in response to the FDA's new guidance due to the coronavirus-led health emergency, has made temporary alterations to its cardiopulmonary product indications for use in ECMO therapy.
Tandem Diabetes Rides on Control-IQ Amid Coronavirus Crisis
by Zacks Equity Research
Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).
Here's Why You Should Hold on to Tandem Diabetes Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.
HEXO in Focus: Stock Moves 9% Higher
by Zacks Equity Research
HEXO saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
QIAGEN Sales Grow on Coronavirus Solutions Ahead of Selloff
by Zacks Equity Research
QIAGEN (QGEN) ramps up production capacity of solutions currently being used for testing purposes.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Thermo Fisher (TMO) Partners With CSL to Expand Pharma Arm
by Zacks Equity Research
Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.
Quest Diagnostics' Self-Collection Coronavirus Kit Gets EUA
by Zacks Equity Research
This kit by Quest Diagnostics (DGX) is suitable for use in children supervised by an adult.
SurModics (SRDX) Up 1.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp Partners With Medable to Expand Technology Ecosystem
by Zacks Equity Research
LabCorp (LH) expands technology ecosystem to accelerate the adoption of decentralized clinical trials by collaborating with Medable.
Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid
by Zacks Equity Research
Zimmer Biomet (ZBH) believes COVID-19 to continue to have a significant unfavorable impact on its sales in the near term.
Here's Why You Should Hold on to Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on robust segmental growth.
Teleflex (TFX) Rides on UroLift Sales Amid Coronavirus Mayhem
by Zacks Equity Research
NeoTract, the acquired business of Teleflex (TFX), continues to perform impressively.
IDEXX Sees Higher Clinical Visits Despite Coronavirus Crisis
by Zacks Equity Research
IDEXX (IDXX) notes a significant improvement in U.S. clinical visit trends across major regions.
Henry Schein Sales Drop on Coronavirus Woes, Costs Rise
by Zacks Equity Research
Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.
Medtronic Gets FDA Nod for Guardian CGM's Android Version
by Zacks Equity Research
Medtronic (MDT) expands reach to diabetic patients by introducing the Guardian Connect CGM system's Android version post its FDA clearance.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.
Here's Why You Should Hold on to Edwards Lifesciences for Now
by Zacks Equity Research
Investors continue to be optimistic about Edwards Lifesciences (EW) on robust demand for products and a promising surgical structural heart business.